0001551163-20-000102.txt : 20201119 0001551163-20-000102.hdr.sgml : 20201119 20201119130652 ACCESSION NUMBER: 0001551163-20-000102 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 37 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201119 DATE AS OF CHANGE: 20201119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOETHICS LTD CENTRAL INDEX KEY: 0000894560 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 870485312 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 033-55254-41 FILM NUMBER: 201328059 BUSINESS ADDRESS: STREET 1: 1661 LAKEVIEW CIRCLE CITY: OGDEN STATE: UT ZIP: 84403 BUSINESS PHONE: (801) 399-3632 MAIL ADDRESS: STREET 1: 1661 LAKEVIEW CIRCLE CITY: OGDEN STATE: UT ZIP: 84403 10-Q 1 10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Form 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2020

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 5(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ______________________________ to ______________________________

Commission File Number 33-55254-41

BIOETHICS, LTD.
(Exact name of registrant as specified in charter)

NEVADA	87-0485312
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

1661 Lakeview Circle, Ogden, Utah	84403
(Address of principal executive offices)	(Zip Code)

(801) 399-3632
(Issuer’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: NONE

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer[ ]Accelerated filer[ ]

Non-accelerated filer[X]Smaller reporting company[X]

Emerging growth company[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the issuer is a shell company (as defined in rule 12b-2 of the Exchange Act). Yes [X] No [ ]

As of November 18, 2020, the issuer had outstanding 1,132,450 shares of common stock, par value $0.001.

BIOETHICS, LTD.

FORM 10-Q

FOR THE QUARTER ENDED SEPTEMBER 30, 2020

INDEX

PART I Financial Information

Item 1.Financial Statements (Unaudited)3

Item 2. Management’s Discussion and Analysis of Financial Condition

and Results of Operations9

Item 3. Quantitative and Qualitative Disclosures About Market Risk10

Item 4. Controls and Procedures10

PART II Other Information

Item 1. Legal Proceedings11

Item 1A. Risk Factors11

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds11

Item 3. Defaults Upon Senior Securities11

Item 4. Mine Safety Disclosures11

Item 5. Other Information11

Item 6. Exhibits12

SIGNATURES12

PART I – FINANCIAL INFORMATION

Item 1.Financial Statements (Unaudited)

BIOETHICS, LTD.

CONTENTS

PAGE

—Unaudited Balance Sheets,

As of September 30, 2020 and December 31, 20194

—Unaudited Statements of Operations,

For the three and nine months ended September 30, 2020 and 20195

—Unaudited Statements of Stockholders’ Equity (Deficit),

For the nine months ended September 30, 2020 and 2019 6

—Unaudited Statements of Cash Flows,

For the nine months ended September 30, 2020 and 2019 7

—Notes to Unaudited Financial Statements for the nine months

ended September 30, 2020 and 20198

BIOETHICS, LTD.
Balance Sheets
(Unaudited)

ASSETS

			September 30,	December 31,
			2020	2019

CURRENT ASSETS

	Cash and cash equivalents		$ 1,069	$ 8,761

		Total Current Assets	1,069	8,761

FIXED ASSETS, NET			298	512


		TOTAL ASSETS	$ 1,367	$ 9,273


LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

CURRENT LIABILITIES

	Accounts payable		$ 49,371	$ 37,783
	Accounts payable - related party		-	1,500
	Accrued interest - related parties		15,593	12,289
	Accrued interest		33,512	19,922
	Convertible notes payable, net of unamortized debt
	discount of $4,281 and $3,716, respectively		30,719	6,284
	Notes payable		150,000	145,000
	Notes payable - related parties		170,134	152,234

		Total Current Liabilities	449,329	375,012

		TOTAL LIABILITIES	449,329	375,012

STOCKHOLDERS' EQUITY (DEFICIT)

	Preferred stock, $0.01 par value; 25,000,000 shares
	authorized, -0- shares issued and outstanding		-	-
	Common stock, $0.001 par value; 250,000,000 shares authorized,
	1,132,450 shares issued and outstanding		1,132	1,132
	Additional paid-in capital		500,482	494,282
	Accumulated deficit		(949,576)	(861,153)

		Total Stockholders' Equity (Deficit)	(447,962)	(365,739)

		TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 1,367	$ 9,273

The accompanying notes are an integral part of these unaudited financial statements.

BIOETHICS, LTD.
Statements of Operations
(Unaudited)

			For the Three Months Ended		For the Nine Months Ended
			September 30,		September 30,
			2020	2019	2020	2019


NET REVENUES			$ -	$ -	$ -	$ -

OPERATING EXPENSES

	General and administrative		12,922	12,009	55,894	40,504

		Total Operating Expenses	12,922	12,009	55,894	40,504

LOSS FROM OPERATIONS			(12,922)	(12,009)	(55,894)	(40,504)

OTHER INCOME (EXPENSES)

	Interest expense		(11,130)	(7,869)	(32,529)	(23,608)

		Total Other Income (Expenses)	(11,130)	(7,869)	(32,529)	(23,608)

NET LOSS BEFORE INCOME TAXES			(24,052)	(19,878)	(88,423)	(64,112)

PROVISION FOR INCOME TAXES			-	-	-	-

NET LOSS			$ (24,052)	$ (19,878)	$ (88,423)	$ (64,112)

BASIC AND DILUTED LOSS PER SHARE			$ (0.02)	$ (0.02)	$ (0.08)	$ (0.06)

WEIGHTED AVERAGE NUMBER OF
SHARES OUTSTANDING			1,132,450	1,132,450	1,132,450	1,132,450

The accompanying notes are an integral part of these unaudited financial statements.

BIOETHICS, LTD.
Statements of Stockholders' Equity (Deficit)
(Unaudited)

	Nine Months Ended September 30, 2020
			Additional		Total
	Common Stock		Paid-In	Accumulated	Stockholders'
	Shares	Amount	Capital	Deficit	Equity (Deficit)
Balance, December 31, 2019	1,132,450	$ 1,132	$ 494,282	$ (861,153)	$ (365,739)
Net loss for the three months ended
March 31, 2020	-	-	-	(36,657)	(36,657)
Balance, March 31, 2020	1,132,450	1,132	494,282	(897,810)	(402,396)
Beneficial conversion feature
on convertible notes payable	-	-	6,200	-	6,200
Net loss for the three months ended
June 30, 2020	-	-	-	(27,714)	(27,714)
Balance, June 30, 2020	1,132,450	1,132	500,482	(925,524)	(423,910)
Net loss for the three months ended
September 30, 2020	-	-	-	(24,052)	(24,052)
Balance, September 30, 2020	1,132,450	$ 1,132	$ 500,482	$ (949,576)	$ (447,962)

	Nine Months Ended September 30, 2019
			Additional		Total
	Common Stock		Paid-In	Accumulated	Stockholders'
	Shares	Amount	Capital	Deficit	Equity (Deficit)
Balance, December 31, 2018	1,132,450	$ 1,132	$ 490,282	$ (759,238)	$ (267,824)
Net loss for the three months ended
March 31, 2019	-	-	-	(26,175)	(26,175)
Balance, March 31, 2019	1,132,450	1,132	490,282	(785,413)	(293,999)
Net loss for the three months ended
June 30, 2019	-	-	-	(18,059)	(18,059)
Balance, June 30, 2019	1,132,450	1,132	490,282	(803,472)	(312,058)
Net loss for the three months ended
September 30, 2019	-	-	-	(19,878)	(19,878)
Balance, September 30, 2019	1,132,450	$ 1,132	$ 490,282	$ (823,350)	$ (331,936)

The accompanying notes are an integral part of these unaudited financial statements.

BIOETHICS, LTD.
Statements of Cash Flows
(Unaudited)

			For the Nine Months Ended
			September 30,
			2020	2019

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss			$ (88,423)	$ (64,112)
Adjustments to reconcile net loss to net cash
used by operating activities:
		Amortization of debt discount	5,635	-
		Depreciation	214	215
Changes in operating assets and liabilities:
		Accounts payable	11,588	7,481
		Accounts payable - related party	(1,500)	(1,000)
		Accrued interest - related parties	3,304	(3,295)
		Accrued interest	13,590	7,957

		Net Cash Used by Operating Activities	(55,592)	(52,754)

CASH FLOWS FROM INVESTING ACTIVITIES			-	-

CASH FLOWS FROM FINANCING ACTIVITIES

		Proceeds from convertible notes payable	25,000	-
		Proceeds from notes payable	5,000	50,000
		Proceeds from notes payable - related parties	23,900	-
		Repayment of notes payable - related parties	(6,000)	(14,686)

		Net Cash Provided by Financing Activities	47,900	35,314

DECREASE IN CASH AND CASH EQUIVALENTS			(7,692)	(17,440)

CASH AND CASH EQUIVALENTS AT
BEGINNING OF PERIOD			8,761	31,698

CASH AND CASH EQUIVALENTS AT
END OF PERIOD			$ 1,069	$ 14,258

SUPPLEMENTAL DISCLOSURES:
	Cash paid for interest		$ 10,000	$ 18,946
	Cash paid for income taxes		$ -	$ -

	Non-cash investing and financing activities:
		Disposal of fully-depreciated fixed asset	$ 187	$ -
		Beneficial conversion feature on convertible note payable	$ 6,200	$ -

The accompanying notes are an integral part of these unaudited financial statements.

BIOETHICS, LTD.

NOTES TO UNAUDITED FINANCIAL STATEMENTS

NINE MONTHS ENDED SEPTEMBER 30, 2020 and 2019

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization - Bioethics, Ltd. (“the Company”) was organized under the laws of the State of Nevada on July 26, 1990. The Company was organized to provide a vehicle for participating in potentially profitable business ventures which may become available through the personal contacts, and at the complete discretion, of the Company’s officers and directors. The Company has, at the present time, not paid any dividends and any dividends that may be paid in the future will depend upon the financial requirements of the Company and other relevant factors.

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows for the nine months ended September 30, 2020 and 2019 have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2019 audited financial statements. The results of operations for the nine months ended September 30, 2020 are not necessarily indicative of the operating results for the full year.

NOTE 2 - RELATED PARTY TRANSACTIONS

Management Compensation - During the nine months ended September 30, 2020 and 2019, the Company did not pay any compensation to its officers and directors.

Beginning August 2017, the Company entered into an oral agreement to pay the Company’s President $500 per month as payment for use of his personal residence as the Company’s office and mailing address. The Company has recorded rent expense of $4,500 during each of the nine months ended September 30, 2020 and 2019, which is included in the general and administrative expenses on the statements of operations. The amount payable at December 31, 2019 was $1,500. During the nine months ended September 30, 2020, the Company paid $6,000, resulting in $-0- payable at September 30, 2020.

On March 8, 2018 the Company entered into a promissory note with a newly-affiliated party in the amount of $43,250. The note is payable on demand and carries interest at 10% per annum. Interest expense for the nine months ended September 30, 2020 and 2019 was $2,597 and $2,588, respectively, resulting in accrued interest of $8,882 and $6,285 at September 30, 2020 and December 31, 2019, respectively. Principal balance on the note at September 30, 2020 and December 31, 2019 was $43,250.

On December 12, 2017, the Company entered into a promissory note with its President in the amount of $107,000. On various dates in 2018 and 2019, the officer advanced the Company an additional $16,670, and the Company made payments of $14,686, resulting in the total note principal balance of $108,984 at December 31, 2019. During the nine months ended September 30, 2020, the Company received an additional $23,900 and paid a total of $6,000 of the principal balance resulting in the total note principal balance of $126,884 at September 30, 2020. The cumulative note balance is uncollateralized, due on demand, and carries interest at 12% per annum. Interest expense on the note for the nine months ended September 30, 2020 and 2019 was $10,707 and $9,431, respectively, of which the Company repaid $10,000 during the nine months ended September 30, 2020, resulting in accrued interest totaling $6,711 and $6,004 at September 30, 2020 and December 31, 2019, respectively.

NOTE 3 - NOTES PAYABLE

On June 14, 2016, the Company issued a promissory note in the principal amount of $35,000 to an unaffiliated lender. The Note is due on demand at any time after its original maturity date of June 14, 2017, and carries an interest rate of 8% per annum. Interest expense for the nine months ended September 30, 2020 and 2019 totaled $2,102 and $2,094, respectively, resulting in accrued interest at September 30, 2020 and December 31, 2019 of $12,036 and $9,934, respectively. Principal balance due on the note at September 30, 2020 and December 31, 2019 was $35,000.

BIOETHICS, LTD.

NOTES TO UNAUDITED FINANCIAL STATEMENTS

NINE MONTHS ENDED SEPTEMBER 30, 2020 and 2019

On August 15, 2018, the Company issued a promissory note in the principal amount of $10,000 to an unaffiliated lender. The Note was due on November 15, 2018 and is now due on demand and carries an interest rate of 12% per annum. Interest expense for the nine months ended September 30, 2020 and 2019 totaled $901 and $898, respectively, resulting in accrued interest at September 30, 2020 and December 31, 2019 of $1,805 and $904, respectively. Principal balance on the note at September 30, 2020 and December 31, 2019 was $10,000.

On November 15, 2018, the Company issued a promissory note in the principal amount of $20,000 to an unaffiliated lender. The Note was due on February 15, 2019 and is now due on demand and carries an interest rate of 12% per annum. Interest expense for the nine months ended September 30, 2020 and 2019 totaled $1,802 and $1,795, respectively, resulting in accrued interest at September 30, 2020 and December 31, 2019 of $3,610 and $1,808, respectively. Principal balance on the note at September 30, 2020 and December 31, 2019 was $20,000.

On December 31, 2018, the Company issued a promissory note in the principal amount of $30,000 to an unaffiliated lender. The Note was due on December 31, 2019 and is now due on demand and carries an interest rate of 12% per annum. Interest expense for the nine months ended September 30, 2020 and 2019 totaled $2,702 and $2,692, respectively, resulting in accrued interest at September 30, 2020 and December 31, 2019 of $5,415 and $2,712, respectively. Principal balance on the note at September 30, 2020 and December 31, 2019 was $30,000.

On January 23, 2019, the Company issued a promissory note in the principal amount of $50,000 to an unaffiliated lender. The Note was due on January 23, 2020 and is now due on demand and carries an interest rate of 12% per annum. Interest expense for the nine months ended September 30, 2020 and 2019 totaled $4,504 and $4,110, respectively, resulting in accrued interest at September 30, 2020 and December 31, 2019 of $9,025 and $4,521, respectively. Principal balance on the note at September 30, 2020 and December 31, 2019 was $50,000.

On May 1, 2020, the Company issued a promissory note in the principal amount of $5,000 to an unaffiliated lender. The Note is due on May 1, 2021 and carries an interest rate of 12% per annum. Interest expense for the nine months ended September 30, 2020 totaled $240, resulting in accrued interest at September 30, 2020 of $240. Principal balance on the note at September 30, 2020 was $5,000.

NOTE 4 – CONVERTIBLE NOTE PAYABLE

On December 18, 2019, the Company issued a convertible promissory note in the original principal amount of $10,000 to a lender. The Note was due on June 18, 2020 and is now due on demand and carries an interest rate of 8% per annum. The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $2.00 per share. The Company recognized a beneficial conversion feature and recorded a debt discount in the amount of $4,000, which is being amortized over the life of the promissory note. At September 30, 2020 and December 31, 2019, the unamortized debt discount was $-0- and $3,716, respectively, and the net convertible note balance was $10,000 and $6,284, respectively. The amortization of debt discount was $3,716 during the nine months ended September 30, 2020. Interest expense for the nine months ended September 30, 2020 totaled $901, resulting in accrued interest at September 30, 2020 and December 31, 2019 of $944 and $43, respectively. Principal balance on the note at September 30, 2020 was $10,000.

On June 9, 2020, the Company issued a convertible promissory note in the original principal amount of $10,000 to a lender. The Note is due on June 9, 2021 and carries an interest rate of 10% per annum. The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $2.50 per share. The Company recognized a beneficial conversion feature and recorded a debt discount in the amount of $6,200, which is being amortized over the life of the promissory note. At September 30, 2020, the unamortized debt discount was $4,281 and the net convertible note balance was $5,719. The amortization of debt discount was $1,919 during the nine months ended September 30, 2020. Interest expense for the nine months ended September 30, 2020 totaled $248, resulting in accrued interest at September 30, 2020 of $248. Principal balance on the note at September 30, 2020 was $10,000.

BIOETHICS, LTD.

NOTES TO UNAUDITED FINANCIAL STATEMENTS

NINE MONTHS ENDED SEPTEMBER 30, 2020 and 2019

assessable shares of common stock of the Company at a conversion rate of $7.00 per share. The Company did not recognize a beneficial conversion feature or debt discount as the conversion price was higher than the market price at the time of issuance of the note. Interest expense for the nine months ended September 30, 2020 totaled $191, resulting in accrued interest at September 30, 2020 of $191. Principal balance on the note at September 30, 2020 was $15,000.

NOTE 5 – EQUITY TRANSACTIONS

On December 2, 2019, the Company amended its articles of incorporation with the state of Nevada increasing the number of authorized common stock of the Company to 250,000,000 shares. There were no equity transactions during the nine months ended September 30, 2020 or 2019, resulting in 1,132,450 shares of common stock issued and outstanding at September 30, 2020 and December 31, 2019.

Effective November 2, 2020, the Company effectuated a 1 share for 10 shares reverse stock split which reduced the issued and outstanding shares of common stock from 11,000,000 shares to 1,132,450 shares. The accompanying financial statements have been retroactively adjusted to reflect this reverse stock split.

NOTE 6 - GOING CONCERN

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has incurred losses since its inception totaling $949,576 and has no on-going operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans, additional sales of its common stock, or through a possible business combination. There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations. In addition, the COVID-19 pandemic could have an impact on our ability to obtain financing to fund the operations. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

NOTE 7 - LOSS PER SHARE

The computation of basic loss per share is based on the weighted average number of shares outstanding during each period.

The following data show the amounts used in computing loss per share for the nine months ended:

		September 30, 2020		September 30, 2019

Net loss (numerator)	$	(88,423)	$	(64,112)
Weighted average shares outstanding (denominator)		1,132,450		1,132,450
Basic and fully diluted net loss per share amount	$	(0.08)	$	(0.06)

The following data show the amounts used in computing loss per share for the three months ended:

		September 30, 2020		September 30, 2019

Net loss (numerator)	$	(24,052)	$	(19,878)
Weighted average shares outstanding (denominator)		1,132,450		1,132,450
Basic and fully diluted net loss per share amount	$	(0.02)	$	(0.02)

The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus the common stock equivalents as detailed in the following chart. For the nine months ended September 30, 2020 and 2019, the inclusion of these shares on the statements of operations would have resulted in a weighted average shares fully diluted number that was anti-dilutive, and as such they are excluded.

BIOETHICS, LTD.

NOTES TO UNAUDITED FINANCIAL STATEMENTS

NINE MONTHS ENDED SEPTEMBER 30, 2020 and 2019

The following data show the fully diluted shares for the nine months ended September 30, 2020 and 2019:

	September 30,
	2020	2019

Basic weighted average shares outstanding	1,132,450	1,132,450
Convertible debt	11,143	-0-
Total	1,143,593	1,132,450

The following data show the fully diluted shares for the three months ended September 30, 2020 and 2019:

	September 30,
	2020	2019

Basic weighted average shares outstanding	1,132,450	1,132,450
Convertible debt	11,143	-0-
Total	1,143,593	1,132,450

NOTE 8 – SUBSEQUENT EVENTS

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion in conjunction with our financial statements, which are included elsewhere in this report. The following information contains forward-looking statements. (See “Forward-Looking Statements” below and “Risk Factors” in our 2019 Form 10K.)

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements reflect the Company’s views with respect to future events based upon information available to it at this time. These forward-looking statements are subject to certain uncertainties and other factors that could cause actual results to differ materially from these statements. These uncertainties and other factors include but are not limited to the risk factors described in our Form 10-K for the year ended December 31, 2019 under the caption “Item 1A. Risk Factors.” The words “anticipates,” “believes,” “estimates,” “expects,” “plans,” “projects,” “targets,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, changes in assumptions, future events or otherwise.

General

The Company is a shell company that conducts no active business operations and is seeking business opportunities for acquisition or participation by the Company.

The Report of Independent Registered Public Accounting Firm on the Company’s December 31, 2019 audited financial statements addresses an uncertainty about the Company’s ability to continue as a going concern, indicating that the Company has incurred losses since its inception and has no on-going operations. The report further indicates that these factors raise substantial doubt about the Company’s ability to continue as a going concern. At September 30, 2020, the Company had a working capital deficit of $448,260 and an accumulated deficit since inception of $949,576. The Company incurred net losses of $88,423 and $64,112 for the nine months ended September 30, 2020 and 2019, respectively. The Company has not entered into any agreements or arrangements for the provision of additional debt or equity financing and there can be no assurance that it will be able to obtain the additional debt or equity capital required to continue its operations.

On July 29, 2020, the Company entered into a non-binding Term Sheet with XCR Diagnostics, Inc. (“XCR”), subject to a number of conditions, to acquire 100% of the ownership of XCR. On July 31, 2020, the Company filed a Form 8-K further describing the proposed transaction. The Company and XCR have not yet negotiated a definitive agreement for the proposed acquisition.

The Three and Nine Months ended September 30, 2020 compared to September 30, 2019

The Company did not conduct any operations during the nine-month periods ended September 30, 2020 or 2019. At September 30, 2020, the Company had cash and total current assets in the amount of $1,069, compared to $8,761 at December 31, 2019. At September 30, 2020, the Company had total current liabilities of $449,329, compared to $375,012 at December 31, 2019. The Company had a working capital deficit of $448,260 at September 30, 2020 compared to $366,251 at December 31, 2019.

The Company did not generate revenues during the nine-month periods ending September 30, 2020 or 2019. The Company incurred general and administrative expenses of $12,922 during the three months ended September 30, 2020, compared to $12,009 during the three months ended September 30, 2019. The Company incurred general and administrative expenses of $55,894 during the nine months ended September 30, 2020, compared to $40,504 during the nine months ended September 30, 2019. Such expenses consist primarily of legal and accounting fees as well as taxes and annual fees required to maintain the Company’s corporate status.

The Company incurred other expenses of $11,130 during the three months ended September 30, 2020 compared to $7,869 during the three months ended September 30, 2019. The Company incurred other expenses of $32,529 during the nine months ended September 30, 2020 compared to $23,608 during the nine months ended September

30, 2019. Total other income and expenses consist of interest expense related to the notes payable due from the Company. Increase in interest expense is due to the increase in debt issued by the Company during the three and nine months ended September 30, 2020 over the same periods ended September 30, 2019.

The Company incurred a net loss of $24,052 during the three months ended September 30, 2020, compared to a net loss of $19,878 during the three months ended September 30, 2019. The Company incurred a net loss of $88,423 during the nine months ended September 30, 2020, compared to a net loss of $64,112 during the nine months ended September 30, 2019. The increase in net loss in 2020 as compared to 2019 was due to the increased professional fees related to the Company maintaining its status and filings with the Securities and Exchange Commission and an increase in interest expense on the recently-issued debt.

The Company has never had substantial ongoing operations. As a result, since its inception on July 26, 1990, the Company had accumulated a deficit of $949,576 as of September 30, 2020.

Liquidity and Capital Resources

Net cash used by operating activities was $55,592 and $52,754 during the nine months ended September 30, 2020 and 2019, respectively.

Net cash provided by investing activities was $-0- during both the nine months ended September 30, 2020 and 2019.

Net cash provided by financing activities was $47,900 and $35,314 during the nine months ended September 30, 2020 and 2019, respectively.

Since the Company does not generate any revenues from operations, it is dependent on sales of securities, loans, or contributions from its stockholders in order to pay its operating costs. In addition, in the event the Company locates a suitable candidate for potential acquisition, the Company will require additional funds to pay the costs of negotiating and completing the acquisition of such candidate. The Company has not entered into any agreement or arrangement for the provision of any additional funding and no assurances can be given that such funding will be available to the Company on terms acceptable to it or at all.

The Company cannot presently foresee the cash requirements of any business opportunity which may ultimately be acquired by the Company. However, since it is likely that any business it acquires will be involved in active business operations, the Company anticipates that an acquisition will result in increased cash requirements as well as increases in the number of employees of the Company.

Off-Balance Sheet Arrangements

The Company has not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.

Critical Accounting Policies

Due to the lack of current operations and limited business activities, the Company does not have any accounting policies that it believes are critical to facilitate an investor’s understanding of the Company’s financial and operating status.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not Applicable. The Company is a “smaller reporting company.”

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer/Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (“the Exchange Act”) as of September 30, 2020, the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer/Chief Financial Officer concluded that our disclosure controls and procedures as of September 30, 2020 were not effective such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer/Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting during the quarter ended September 30, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Part II---OTHER INFORMATION

Item 1. Legal Proceedings.

The Company is not a party to any material pending legal proceedings and, to the best of its knowledge; its properties are not the subject of any such proceedings.

Item 1A. Risk Factors.

Not Applicable. The Company is a “smaller reporting company.”

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

Not Applicable.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5. Other Information.

None.

Item 6.Exhibits

The following documents are included as exhibits to this report:

(a)Exhibits

Exhibit Number	SEC Reference Number	Title of Document	Location

31.1	31	Section 302 Certification of Chief Executive and Chief Financial Officer	This Filing
32.1	32	Section 1350 Certification of Chief Executive and Chief Financial Officer	This Filing
101.INS**		XBRL Instance Document	This Filing
101.SCH**		XBRL Taxonomy Extension Schema	This Filing
101.CAL**		XBRL Taxonomy Extension Calculation Linkbase	This Filing
101.DEF**		XBRL Taxonomy Extension Definition Linkbase	This Filing
101.LAB**		XBRL Taxonomy Extension Label Linkbase	This Filing
101.PRE**		XBRL Taxonomy Extension Presentation Linkbase	This Filing

**XBRL information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement or prospectus to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Bioethics, Ltd.


Date: November 18, 2020	By /s/ Mark A. Scharmann
	Mark A. Scharmann
	President, Chief Executive Officer and
	Chief Financial Officer
	(Principal Executive and Financial Officer)

EX-31 2 311.htm

Exhibit 31.1

I, Mark A. Scharmann, certify that:

1.I have reviewed this report on Form 10-Q of Bioethics, Ltd;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


	Bioethics, Ltd.
Date: November 18, 2020	By /s/ Mark A. Scharmann
	Mark A. Scharmann
	President, Chief Executive Officer and
	Chief Financial Officer
	(Principal Executive and Financial Officer)

EX-32 3 321.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Bioethics, Ltd. (the “Company”) on Form 10-Q for the fiscal quarter ended September 30, 2020 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Mark A. Scharmann, President, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	Bioethics, Ltd.


Date: November 18, 2020	By /s/ Mark A. Scharmann
	Mark A. Scharmann
	President, Chief Executive Officer and
	Chief Financial Officer
	(Principal Executive and Financial Officer)

EX-101.INS 4 both-20200930.xml 0000894560 --12-31 10-Q true 2020-09-30 false 33-55254-41 BIOETHICS LTD NV 87-0485312 1661 Lakeview Circle Ogden UT 84403 801 399 3632 Yes Yes Non-accelerated Filer true false true 1132450 false 2020 Q3

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization - Bioethics, Ltd. (the Company) was organized under the laws of the State of Nevada on July 26, 1990.  The Company was organized to provide a vehicle for participating in potentially profitable business ventures which may become available through the personal contacts, and at the complete discretion, of the Companys officers and directors.  The Company has, at the present time, not paid any dividends and any dividends that may be paid in the future will depend upon the financial requirements of the Company and other relevant factors. The accompanying financial statements have been prepared by the Company without audit.  In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows for the nine months ended September 30, 2020 and 2019 have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted.  It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Companys December 31, 2019 audited financial statements.  The results of operations for the nine months ended September 30, 2020 are not necessarily indicative of the operating results for the full year.

NOTE 2 - RELATED PARTY TRANSACTIONS Management Compensation - During the nine months ended September 30, 2020 and 2019, the Company did not pay any compensation to its officers and directors. Beginning August 2017, the Company entered into an oral agreement to pay the Companys President $500 per month as payment for use of his personal residence as the Companys office and mailing address.  The Company has recorded rent expense of $4,500 during each of the nine months ended September 30, 2020 and 2019, which is included in the general and administrative expenses on the statements of operations.  The amount payable at December 31, 2019 was $1,500.  During the nine months ended September 30, 2020, the Company paid $6,000, resulting in $0 payable at September 30, 2020.   On March 8, 2018 the Company entered into a promissory note with a newly-affiliated party in the amount of $43,250. The note is payable on demand and carries interest at 10% per annum.  Interest expense for the nine months ended September 30, 2020 and 2019 was $2,597 and $2,588, respectively, resulting in accrued interest of $8,882 and $6,285 at September 30, 2020 and December 31, 2019, respectively.  Principal balance on the note at September 30, 2020 and December 31, 2019 was $43,250.   On December 12, 2017, the Company entered into a promissory note with its President in the amount of $107,000.  On various dates in 2018 and 2019, the officer advanced the Company an additional $16,670, and the Company made payments of $14,686, resulting in the total note principal balance of $108,984 at December 31, 2019.  During the nine months ended September 30, 2020, the Company received an additional $23,900 and paid a total of $6,000 of the principal balance resulting in the total note principal balance of $126,884 at September 30, 2020.  The cumulative note balance is uncollateralized, due on demand, and carries interest at 12% per annum.  Interest expense on the note for the nine months ended September 30, 2020 and 2019 was $10,707 and $9,431, respectively, of which the Company repaid $10,000 during the nine months ended September 30, 2020, resulting in accrued interest totaling $6,711 and $6,004 at September 30, 2020 and December 31, 2019, respectively.

NOTE 4 CONVERTIBLE NOTE PAYABLE  On December 18, 2019, the Company issued a convertible promissory note in the original principal amount of $10,000 to a lender. The Note was due on June 18, 2020 and is now due on demand and carries an interest rate of 8% per annum. The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $2.00 per share.  The Company recognized a beneficial conversion feature and recorded a debt discount in the amount of $4,000, which is being amortized over the life of the promissory note.  At September 30, 2020 and December 31, 2019, the unamortized debt discount was $-0- and $3,716, respectively, and the net convertible note balance was $10,000 and $6,284, respectively.  The amortization of debt discount was $3,716 during the nine months ended September 30, 2020.  Interest expense for the nine months ended September 30, 2020 totaled $901, resulting in accrued interest at September 30, 2020 and December 31, 2019 of $944 and $43, respectively.  Principal balance on the note at September 30, 2020 was $10,000. On June 9, 2020, the Company issued a convertible promissory note in the original principal amount of $10,000 to a lender. The Note is due on June 9, 2021 and carries an interest rate of 10% per annum. The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $2.50 per share.  The Company recognized a beneficial conversion feature and recorded a debt discount in the amount of $6,200, which is being amortized over the life of the promissory note.  At September 30, 2020, the unamortized debt discount was $4,281 and the net convertible note balance was $5,719.  The amortization of debt discount was $1,919 during the nine months ended September 30, 2020.  Interest expense for the nine months ended September 30, 2020 totaled $248, resulting in accrued interest at September 30, 2020 of $248.  Principal balance on the note at September 30, 2020 was $10,000. On August 3, 2020, the Company issued a convertible promissory note in the original principal amount of $15,000 to a lender. The Note is due on August 3, 2021 and carries an interest rate of 8% per annum. The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $7.00 per share.  The Company did not recognize a beneficial conversion feature or debt discount as the conversion price was higher than the market price at the time of issuance of the note.  Interest expense for the nine months ended September 30, 2020 totaled $191, resulting in accrued interest at September 30, 2020 of $191. Principal balance on the note at September 30, 2020 was $15,000.

10000

The Note was due on June 18, 2020 and is now due on demand and carries an interest rate of 8% per annum.

The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $2.00 per share.

The Note is due on June 9, 2021 and carries an interest rate of 10% per annum

The Note is due on August 3, 2021 and carries an interest rate of 8% per annum

191

NOTE 5 EQUITY TRANSACTIONS On December 2, 2019, the Company amended its articles of incorporation with the state of Nevada increasing the number of authorized common stock of the Company to 250,000,000 shares.  There were no equity transactions during the nine months ended September 30, 2020 or 2019, resulting in 1,132,450 shares of common stock issued and outstanding at September 30, 2020 and December 31, 2019. Effective November 2, 2020, the Company effectuated a 1 share for 10 shares reverse stock split which reduced the issued and outstanding shares of common stock from 11,000,000 shares to 1,132,450 shares.  The accompanying financial statements have been retroactively adjusted to reflect this reverse stock split.

250000000

1132450

the Company effectuated a 1 share for 10 shares reverse stock split which reduced the issued and outstanding shares of common stock from 11,000,000 shares to 1,132,450 shares

NOTE 6 - GOING CONCERN The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern.  However, the Company has incurred losses since its inception totaling $949,576 and has no on-going operations.  These factors raise substantial doubt about the ability of the Company to continue as a going concern.  In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans, additional sales of its common stock, or through a possible business combination.  There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations.  In addition, the COVID-19 pandemic could have an impact on our ability to obtain financing to fund the operations. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

NOTE 8  SUBSEQUENT EVENTS Effective November 2, 2020, the Company effectuated a 1 share for 10 shares reverse stock split which reduced the issued and outstanding shares of common stock from 11,000,000 shares to 1,132,450 shares.  The accompanying financial statements have been retroactively adjusted to reflect this reverse stock split.

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2020	Jul. 28, 2020
Details
Registrant CIK	0000894560
Fiscal Year End	--12-31
Registrant Name	BIOETHICS LTD
SEC Form	10-Q
Period End date	Sep. 30, 2020
Tax Identification Number (TIN)	87-0485312
Number of common stock shares outstanding		1,132,450
Filer Category	Non-accelerated Filer
Current with reporting	Yes
Interactive Data Current	Yes
Shell Company	true
Small Business	true
Emerging Growth Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	33-55254-41
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	1661 Lakeview Circle
Entity Address, City or Town	Ogden
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84403
Country Region	801
City Area Code	399
Local Phone Number	3632
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3

XML 11 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets - USD ($)	Sep. 30, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash and cash equivalents	$ 1,069	$ 8,761
Total Current Assets	1,069	8,761
FIXED ASSETS, NET	298	512
TOTAL ASSETS	1,367	9,273
CURRENT LIABILITIES
Accounts payable	49,371	37,783
Accounts payable - related party	0	1,500
Accrued interest - related parties	15,593	12,289
Accrued interest	33,512	19,922
discount of $4,281 and $3,716, respectively	30,719	6,284
Notes payable	150,000	145,000
Notes payable - related parties	170,134	152,234
Total Current Liabilities	449,329	375,012
TOTAL LIABILITIES	449,329	375,012
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, $0.01 par value; 25,000,000 shares authorized-0- shares issued and outstanding	0	0
Common stock, $0.001 par value; 250,000,000 shares authorized, 1,132,450 shares issued and outstanding	1,132	1,132
Additional paid-in capital	500,482	494,282
Accumulated deficit	(949,576)	(861,153)
Total Stockholders' Equity (Deficit)	(447,962)	(365,739)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 1,367	$ 9,273

XML 12 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets - Parenthetical - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Details
Debt Instrument, Unamortized Discount	$ 4,281	$ 3,716
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	25,000,000	25,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	250,000,000	250,000,000
Common Stock, Shares, Issued	1,132,450	1,132,450
Common Stock, Shares, Outstanding	1,132,450	1,132,450

XML 13 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
Statements of Operations - USD ($)	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Details
NET REVENUES	$ 0	$ 0	$ 0	$ 0
OPERATING EXPENSES
General and administrative	12,922	12,009	55,894	40,504
Total Operating Expenses	12,922	12,009	55,894	40,504
LOSS FROM OPERATIONS	(12,922)	(12,009)	(55,894)	(40,504)
OTHER INCOME (EXPENSES)
Interest expense	(11,130)	(7,869)	(32,529)	(23,608)
Total Other Income (Expenses)	(11,130)	(7,869)	(32,529)	(23,608)
NET LOSS BEFORE INCOME TAXES	(24,052)	(19,878)	(88,423)	(64,112)
PROVISION FOR INCOME TAXES	0	0	0	0
NET LOSS	$ (24,052)	$ (19,878)	$ (88,423)	$ (64,112)
BASIC AND DILUTED LOSS PER SHARE	$ (0.02)	$ (0.02)	$ (0.08)	$ (0.06)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	1,132,450	1,132,450	1,132,450	1,132,450

XML 14 R5.htm IDEA: XBRL DOCUMENT

Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock	Additional Paid-in Capital	Retained Earnings	Total
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2018	$ 1,132	$ 490,282	$ (759,238)	$ (267,824)
Shares, Outstanding, Beginning Balance at Dec. 31, 2018	1,132,450
NET LOSS	$ 0	0	(26,175)	(26,175)
Stockholders' Equity Attributable to Parent, Ending Balance at Mar. 31, 2019	$ 1,132	490,282	(785,413)	(293,999)
Shares, Outstanding, Ending Balance at Mar. 31, 2019	1,132,450
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2018	$ 1,132	490,282	(759,238)	(267,824)
Shares, Outstanding, Beginning Balance at Dec. 31, 2018	1,132,450
NET LOSS				(64,112)
Stockholders' Equity Attributable to Parent, Ending Balance at Sep. 30, 2019	$ 1,132	490,282	(823,350)	(331,936)
Shares, Outstanding, Ending Balance at Sep. 30, 2019	1,132,450
Beneficial conversion feature on convertible notes payable				0
Stockholders' Equity Attributable to Parent, Beginning Balance at Mar. 31, 2019	$ 1,132	490,282	(785,413)	(293,999)
Shares, Outstanding, Beginning Balance at Mar. 31, 2019	1,132,450
NET LOSS	$ 0	0	(18,059)	(18,059)
Stockholders' Equity Attributable to Parent, Ending Balance at Jun. 30, 2019	$ 1,132	490,282	(803,472)	(312,058)
Shares, Outstanding, Ending Balance at Jun. 30, 2019	1,132,450
NET LOSS	$ 0	0	(19,878)	(19,878)
Stockholders' Equity Attributable to Parent, Ending Balance at Sep. 30, 2019	$ 1,132	490,282	(823,350)	(331,936)
Shares, Outstanding, Ending Balance at Sep. 30, 2019	1,132,450
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2019	$ 1,132	494,282	(861,153)	(365,739)
Shares, Outstanding, Beginning Balance at Dec. 31, 2019	1,132,450
NET LOSS	$ 0	0	(36,657)	(36,657)
Stockholders' Equity Attributable to Parent, Ending Balance at Mar. 31, 2020	$ 1,132	494,282	(897,810)	(402,396)
Shares, Outstanding, Ending Balance at Mar. 31, 2020	1,132,450
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2019	$ 1,132	494,282	(861,153)	(365,739)
Shares, Outstanding, Beginning Balance at Dec. 31, 2019	1,132,450
NET LOSS				(88,423)
Stockholders' Equity Attributable to Parent, Ending Balance at Sep. 30, 2020	$ 1,132	500,482	(949,576)	(447,962)
Shares, Outstanding, Ending Balance at Sep. 30, 2020	1,132,450
Beneficial conversion feature on convertible notes payable				6,200
Stockholders' Equity Attributable to Parent, Beginning Balance at Mar. 31, 2020	$ 1,132	494,282	(897,810)	(402,396)
Shares, Outstanding, Beginning Balance at Mar. 31, 2020	1,132,450
NET LOSS	$ 0	0	(27,714)	(27,714)
Stockholders' Equity Attributable to Parent, Ending Balance at Jun. 30, 2020	$ 1,132	500,482	(925,524)	(423,910)
Shares, Outstanding, Ending Balance at Jun. 30, 2020	1,132,450
Beneficial conversion feature on convertible notes payable	$ 0	6,200	0	6,200
NET LOSS	0	0	(24,052)	(24,052)
Stockholders' Equity Attributable to Parent, Ending Balance at Sep. 30, 2020	$ 1,132	$ 500,482	$ (949,576)	$ (447,962)
Shares, Outstanding, Ending Balance at Sep. 30, 2020	1,132,450

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

XML 15 R6.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows - USD ($)	9 Months Ended
Statements of Cash Flows - USD ($)	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
NET LOSS	$ (88,423)	$ (64,112)
Adjustments to reconcile net loss to net cash
Amortization of debt discount	5,635	0
Depreciation	214	215
Changes in operating assets and liabilities:
Accounts payable	11,588	7,481
Accounts payable - related party	(1,500)	(1,000)
Accrued interest - related parties	3,304	(3,295)
Accrued interest	13,590	7,957
Net Cash Used by Operating Activities	(55,592)	(52,754)
CASH FLOWS FROM INVESTING ACTIVITIES	0	0
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from convertible notes payable	25,000	0
Proceeds from notes payable	5,000	50,000
Proceeds from notes payable - related parties	23,900	0
Repayment of notes payable - related parties	(6,000)	(14,686)
Net Cash Provided by Financing Activities	47,900	35,314
DECREASE IN CASH AND CASH EQUIVALENTS	(7,692)	(17,440)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	8,761	31,698
CASH AND CASH EQUIVALENTS AT END OF PERIOD	1,069	14,258
SUPPLEMENTAL DISCLOSURES:
Cash paid for interest	10,000	18,946
Cash paid for income taxes	0	0
Noncash Investing and Financing Items
Disposal of fully-depreciated fixed asset	187	0
Beneficial conversion feature on convertible notes payable	$ 6,200	$ 0

XML 16 R7.htm IDEA: XBRL DOCUMENT

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2020

Notes

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

XML 17 R8.htm IDEA: XBRL DOCUMENT

NOTE 2 RELATED PARTY TRANSACTIONS

9 Months Ended

Sep. 30, 2020

Notes

NOTE 2 RELATED PARTY TRANSACTIONS

NOTE 2 - RELATED PARTY TRANSACTIONS

Management Compensation - During the nine months ended September 30, 2020 and 2019, the Company did not pay any compensation to its officers and directors.

XML 18 R9.htm IDEA: XBRL DOCUMENT

NOTE 3 - NOTES PAYABLE

9 Months Ended

Sep. 30, 2020

Notes

NOTE 3 - NOTES PAYABLE

XML 19 R10.htm IDEA: XBRL DOCUMENT

NOTE 4 - CONVERTIBLE NOTE PAYABLE

9 Months Ended

Sep. 30, 2020

Notes

NOTE 4 - CONVERTIBLE NOTE PAYABLE

NOTE 4 – CONVERTIBLE NOTE PAYABLE

On August 3, 2020, the Company issued a convertible promissory note in the original principal amount of $15,000 to a lender. The Note is due on August 3, 2021 and carries an interest rate of 8% per annum. The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $7.00 per share. The Company did not recognize a beneficial conversion feature or debt discount as the conversion price was higher than the market price at the time of issuance of the note. Interest expense for the nine months ended September 30, 2020 totaled $191, resulting in accrued interest at September 30, 2020 of $191. Principal balance on the note at September 30, 2020 was $15,000.

XML 20 R11.htm IDEA: XBRL DOCUMENT

NOTE 5 - EQUITY TRANSACTIONS

9 Months Ended

Sep. 30, 2020

Notes

NOTE 5 - EQUITY TRANSACTIONS

NOTE 5 – EQUITY TRANSACTIONS

XML 21 R12.htm IDEA: XBRL DOCUMENT

NOTE 6 - GOING CONCERN

9 Months Ended

Sep. 30, 2020

Notes

NOTE 6 - GOING CONCERN

XML 22 R13.htm IDEA: XBRL DOCUMENT

NOTE 7 - LOSS PER SHARE

9 Months Ended

Sep. 30, 2020

Notes

NOTE 7 - LOSS PER SHARE

The computation of basic loss per share is based on the weighted average number of shares outstanding during each period.

The following data show the amounts used in computing loss per share for the nine months ended:

		September 30, 2020		September 30, 2019

Net loss (numerator)	$	(88,423)	$	(64,112)
Weighted average shares outstanding (denominator)		1,132,450		1,132,450
Basic and fully diluted net loss per share amount	$	(0.08)	$	(0.06)

The following data show the amounts used in computing loss per share for the three months ended:

		September 30, 2020		September 30, 2019

Net loss (numerator)	$	(24,052)	$	(19,878)
Weighted average shares outstanding (denominator)		1,132,450		1,132,450
Basic and fully diluted net loss per share amount	$	(0.02)	$	(0.02)

The following data show the fully diluted shares for the nine months ended September 30, 2020 and 2019:

	September 30,
	2020	2019

Basic weighted average shares outstanding	1,132,450	1,132,450
Convertible debt	11,143	0
Total	1,143,593	1,132,450

The following data show the fully diluted shares for the three months ended September 30, 2020 and 2019:

	September 30,
	2020	2019

Basic weighted average shares outstanding	1,132,450	1,132,450
Convertible debt	11,143	0
Total	1,143,593	1,132,450

XML 23 R14.htm IDEA: XBRL DOCUMENT

NOTE 8 - SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2020

Notes

NOTE 8 - SUBSEQUENT EVENTS

NOTE 8 – SUBSEQUENT EVENTS

XML 24 R15.htm IDEA: XBRL DOCUMENT

NOTE 7 - LOSS PER SHARE: Schedule of earnings per share (Tables)

9 Months Ended

Sep. 30, 2020

Tables/Schedules

Schedule of earnings per share

The following data show the amounts used in computing loss per share for the nine months ended:

		September 30, 2020		September 30, 2019

Net loss (numerator)	$	(88,423)	$	(64,112)
Weighted average shares outstanding (denominator)		1,132,450		1,132,450
Basic and fully diluted net loss per share amount	$	(0.08)	$	(0.06)

The following data show the amounts used in computing loss per share for the three months ended:

		September 30, 2020		September 30, 2019

Net loss (numerator)	$	(24,052)	$	(19,878)
Weighted average shares outstanding (denominator)		1,132,450		1,132,450
Basic and fully diluted net loss per share amount	$	(0.02)	$	(0.02)

XML 25 R16.htm IDEA: XBRL DOCUMENT

NOTE 7 - LOSS PER SHARE: Schedule of fully diluted shares (Tables)

9 Months Ended

Sep. 30, 2020

Tables/Schedules

Schedule of fully diluted shares

The following data show the fully diluted shares for the nine months ended September 30, 2020 and 2019:

	September 30,
	2020	2019

Basic weighted average shares outstanding	1,132,450	1,132,450
Convertible debt	11,143	0
Total	1,143,593	1,132,450

The following data show the fully diluted shares for the three months ended September 30, 2020 and 2019:

	September 30,
	2020	2019

Basic weighted average shares outstanding	1,132,450	1,132,450
Convertible debt	11,143	0
Total	1,143,593	1,132,450

- Definition

Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959

+ Details

XML 26 R17.htm IDEA: XBRL DOCUMENT

NOTE 2 RELATED PARTY TRANSACTIONS (Details) - USD ($)	3 Months Ended		9 Months Ended		24 Months Ended
NOTE 2 RELATED PARTY TRANSACTIONS (Details) - USD ($)	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Mar. 08, 2018	Dec. 12, 2017
Notes payable - related parties	$ 170,134		$ 170,134		$ 152,234
Interest Expense	11,130	$ 7,869	32,529	$ 23,608
Director 1
Operating Leases, Rent Expense			4,500	4,500
Notes payable - related parties	0		0		1,500
Repayments of Related Party Debt			6,000
Newly Affiliated Party
Debt Instrument, Face Amount						$ 43,250
Debt Instrument, Interest Rate, Stated Percentage						10.00%
Interest Expense			2,597	2,588
Interest Payable, Current	8,882		8,882		6,285
Long-term Debt, Gross	43,250		43,250		43,250
Sole Officer And Director
Notes payable - related parties	$ 126,884		126,884		108,984
Repayments of Related Party Debt			$ 6,000		14,686
Debt Instrument, Face Amount							$ 107,000
Debt Instrument, Interest Rate, Stated Percentage	12.00%		12.00%
Interest Expense			$ 10,707	$ 9,431
Interest Payable, Current	$ 6,711		6,711		6,004
Proceeds from Related Party Debt			23,900		$ 16,670
Repayment of Notes Receivable from Related Parties			$ 10,000

XML 27 R18.htm IDEA: XBRL DOCUMENT

NOTE 3 - NOTES PAYABLE (Details) - USD ($)	3 Months Ended		9 Months Ended
NOTE 3 - NOTES PAYABLE (Details) - USD ($)	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	May 01, 2020	Dec. 31, 2019	Jan. 23, 2019	Dec. 31, 2018	Nov. 15, 2018	Aug. 15, 2018	Jun. 14, 2016
Interest Expense	$ 11,130	$ 7,869	$ 32,529	$ 23,608
Promissory Note 1
Debt Instrument, Face Amount											$ 35,000
Debt Instrument, Interest Rate, Stated Percentage											8.00%
Interest Expense			2,102	2,094
Interest Payable, Current	12,036		12,036			$ 9,934
Long-term Debt, Gross	35,000		35,000
Promissory Note 2
Debt Instrument, Face Amount										$ 10,000
Debt Instrument, Interest Rate, Stated Percentage										12.00%
Interest Expense			901	898
Interest Payable, Current	1,805		1,805			904
Long-term Debt, Gross	10,000		10,000
Promissory Note 3
Debt Instrument, Face Amount									$ 20,000
Debt Instrument, Interest Rate, Stated Percentage									12.00%
Interest Expense			1,802	1,795
Interest Payable, Current	3,610		3,610			1,808
Long-term Debt, Gross	20,000		20,000
Promissory Note 4
Debt Instrument, Face Amount								$ 30,000
Debt Instrument, Interest Rate, Stated Percentage								12.00%
Interest Expense			2,702	2,692
Interest Payable, Current	5,415		5,415			2,712
Long-term Debt, Gross	30,000		30,000
Promissory Note 5
Debt Instrument, Face Amount							$ 50,000
Debt Instrument, Interest Rate, Stated Percentage							12.00%
Interest Expense			4,504	$ 4,110
Interest Payable, Current	9,025		9,025			$ 4,521
Long-term Debt, Gross	50,000		50,000
Promissory Note 6
Debt Instrument, Face Amount					$ 5,000
Debt Instrument, Interest Rate, Stated Percentage					12.00%
Interest Expense			240
Interest Payable, Current	240		240
Long-term Debt, Gross	$ 5,000		$ 5,000

XML 28 R19.htm IDEA: XBRL DOCUMENT

NOTE 4 - CONVERTIBLE NOTE PAYABLE (Details) - USD ($)	3 Months Ended		9 Months Ended
NOTE 4 - CONVERTIBLE NOTE PAYABLE (Details) - USD ($)	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Debt Instrument, Unamortized Discount	$ 4,281		$ 4,281		$ 3,716
Amortization of debt discount			5,635	$ 0
Interest Expense	11,130	$ 7,869	32,529	$ 23,608
A Lender
Debt Instrument, Face Amount	10,000		$ 10,000
Debt Instrument, Payment Terms			The Note was due on June 18, 2020 and is now due on demand and carries an interest rate of 8% per annum.
Debt Instrument, Convertible, Terms of Conversion Feature			The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $2.00 per share.
Debt Instrument, Unamortized Discount	4,000		$ 4,000
Debt Instrument, Unamortized Discount, Current	0		0		3,716
Long-term Debt, Gross	10,000		10,000		6,284
Amortization of debt discount			3,716
Interest Expense			901
Interest Payable, Current	944		944		$ 43
A Lender (2)
Debt Instrument, Face Amount	10,000		$ 10,000
Debt Instrument, Payment Terms			The Note is due on June 9, 2021 and carries an interest rate of 10% per annum
Debt Instrument, Convertible, Terms of Conversion Feature			The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $2.50 per share.
Debt Instrument, Unamortized Discount	6,200		$ 6,200
Debt Instrument, Unamortized Discount, Current	4,281		4,281
Long-term Debt, Gross	5,719		5,719
Amortization of debt discount			1,919
Interest Expense			248
Interest Payable, Current	248		248
A Lender (3)
Debt Instrument, Face Amount	15,000		$ 15,000
Debt Instrument, Payment Terms			The Note is due on August 3, 2021 and carries an interest rate of 8% per annum
Debt Instrument, Convertible, Terms of Conversion Feature			The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $7.00 per share.
Interest Expense			$ 191
Interest Payable, Current	$ 191		$ 191

XML 29 R20.htm IDEA: XBRL DOCUMENT

NOTE 5 - EQUITY TRANSACTIONS (Details) - shares	Nov. 02, 2020	Sep. 30, 2020	Dec. 31, 2019
Details
Common Stock, Shares Authorized		250,000,000	250,000,000
Common Stock, Shares, Issued		1,132,450	1,132,450
Common Stock, Shares, Outstanding		1,132,450	1,132,450
Stockholders' Equity, Reverse Stock Split	the Company effectuated a 1 share for 10 shares reverse stock split which reduced the issued and outstanding shares of common stock from 11,000,000 shares to 1,132,450 shares

XML 30 R21.htm IDEA: XBRL DOCUMENT

NOTE 7 - LOSS PER SHARE: Schedule of earnings per share (Details) - USD ($)			3 Months Ended						9 Months Ended
	Sep. 30, 2020	Mar. 31, 2019	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Details
NET LOSS			$ (24,052)	$ (27,714)	$ (36,657)	$ (19,878)	$ (18,059)	$ (26,175)	$ (88,423)	$ (64,112)
Weighted average shares outstanding (denominator)	1,132,450	1,132,450	1,132,450			1,132,450			1,132,450	1,132,450
Basic and fully diluted net loss per share amount			$ (0.02)			$ (0.02)			$ (0.08)	$ (0.06)

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

+ Details

XML 31 R22.htm IDEA: XBRL DOCUMENT

NOTE 7 - LOSS PER SHARE: Schedule of fully diluted shares (Details) - shares			3 Months Ended		9 Months Ended
	Sep. 30, 2020	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Details
Basic weighted average shares outstanding	1,132,450	1,132,450	1,132,450	1,132,450	1,132,450	1,132,450
Convertible debt	11,143	0	11,143	0
Total	1,143,593	1,132,450	1,143,593	1,132,450

XML 32 R23.htm IDEA: XBRL DOCUMENT

NOTE 8 - SUBSEQUENT EVENTS (Details)	9 Months Ended
NOTE 8 - SUBSEQUENT EVENTS (Details)	Sep. 30, 2020
Details
Subsequent Event, Description	Effective November 2, 2020, the Company effectuated a 1 share for 10 shares reverse stock split which reduced the issued and outstanding shares of common stock from 11,000,000 shares to 1,132,450 shares. The accompanying financial statements have been retroactively adjusted to reflect this reverse stock split.